Market Assessment: Biopharma Company
Early-Stage Biopharma Company Needs Strategy and Research Support to Inform Prioritization
Robin LaChapelle, Arrivent
“The RNA team has helped us with tax and financial reporting-oriented valuation work. Its nice to work with a firm that not only understands the intricacies of reporting requirements but actually understands the drug development business.”
Stig Hansen, Kimia Therapeutics
“I’ve worked with the RNA team for over a decade across my current and previous companies. They are our go to valuation firm for valuation because they know the industry, are responsive and understand the nuances that drive transactions just as much as accounting.”
Market Assessment and Valuation: 505(b)(2) Cardiology Drug Therapy
Market Assessment and Valuation for a 505(b)(2) Cardiology Drug Therapy
Corporate Strategy: Growth Options for Medtech in Heart Failure
Comprehensive Assessment of Growth Options and a Plan for a Strategic Pivot
Jake Frank, SmithRx
“I love the RNA team. They get healthcare and we’ve worked with the team both in valuation advisory capacities as well as on strategic projects for us as we take SmithRx to the next level. These guys get it!”
Fairness Opinion: De-SPAC Transaction for Inflammatory Disorders Therapeutics Company
SPAC Seeks Independent Valuation of Target
Fairness Opinion: De-SPAC Transaction for T-Cell Therapeutics Company
SPAC Seeks Independent Valuation of Target Company in T-Cell Therapeutics
Fairness Opinion: De-SPAC Transaction for Private Biotech Company
SPAC Seeks Independent Valuation of Target in Mental Health Disorders
